EWTX
Edgewise Therapeutics, Inc.
$39.17
-0.14
(-0.36%)
Mkt Cap
4.21B
Volume
1,009,168
52W Range
15.23-48.51
Sector
Healthcare
Beta
0.28
EPS (TTM)
-1.85 USD
P/E Ratio
-15.23
Revenue (TTM)
0 USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (167.79M) | (133.81M) | (100.16M) | (67.64M) | (42.81M) | (17.05M) | (9.49M) |
| EPS | -1.63 | -1.45 | -1.57 | -1.26 | -0.86 | -0.35 | -0.19 |
| Free Cash Flow | (143.82M) | (110.34M) | (97.69M) | (58.18M) | (34.17M) | (14.84M) | (9.35M) |
| FCF / Share | -1.40 | -1.19 | -1.53 | -1.09 | -0.69 | -0.30 | -0.19 |
| Operating CF | (143.82M) | (109.03M) | (91.95M) | (52.63M) | (33.51M) | (14.63M) | (9.17M) |
| Total Assets | 552.60M | 486.82M | 340.04M | 367.10M | 285.23M | 131.14M | 24.54M |
| Total Debt | 3.99M | 4.74M | 5.41M | 4.41M | 0 | 160.21M | 0 |
| Cash & Equiv | 61.15M | 41.67M | 86.10M | 21.99M | 15.57M | 104.92M | 23.65M |
| Book Value | 522.26M | 459.22M | 318.83M | 346.72M | 274.38M | (33.42M) | (16.85M) |
| Return on Equity | -0.32 | -0.29 | -0.31 | -0.20 | -0.16 | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (57.33M) | (49.01M) | (50.22M) | (40.67M) | (36.12M) | (40.80M) | (39.66M) | (34.13M) | (31.50M) | (28.52M) | (30.14M) | (25.71M) |
| EPS | -0.53 | -0.46 | -0.47 | -0.39 | -0.34 | -0.43 | -0.42 | -0.36 | -0.34 | -0.33 | -0.47 | -0.41 |
| Free Cash Flow | (43.54M) | (42.80M) | (38.41M) | (34.87M) | (32.63M) | (37.91M) | (27.23M) | (27.89M) | (26.32M) | (28.89M) | (26.99M) | (22.52M) |
| FCF / Share | -0.40 | -0.40 | -0.37 | -0.33 | -0.31 | -0.40 | -0.29 | -0.30 | -0.28 | -0.33 | -0.42 | -0.35 |
| Operating CF | (43.51M) | (42.54M) | (38.59M) | (34.78M) | (32.58M) | (37.87M) | (26.96M) | (27.37M) | (26.10M) | (28.60M) | (26.83M) | (22.06M) |
| Total Assets | 479.69M | 518.52M | 552.60M | 583.47M | 613.33M | 454.39M | 486.82M | 511.28M | 531.65M | 553.81M | 340.04M | 311.36M |
| Total Debt | 3.59M | 3.79M | 3.99M | 4.18M | 4.37M | 4.56M | 4.74M | 4.44M | 4.99M | 5.25M | 5.41M | 5.53M |
| Cash & Equiv | 72.32M | 33.21M | 61.15M | 46.00M | 43.40M | 49.92M | 41.67M | 44.81M | 43.48M | 30.26M | 86.10M | 32.96M |
| Book Value | 448.08M | 493.20M | 522.26M | 558.65M | 589.07M | 429.72M | 459.22M | 488.88M | 510.47M | 534.94M | 318.83M | 290.43M |
| Return on Equity | -0.13 | -0.10 | -0.10 | -0.07 | -0.06 | -0.09 | -0.09 | -0.07 | -0.06 | -0.05 | -0.09 | -0.09 |
EWTX News
Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 Transcript
Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500
Biotech Options Buzz: UTHR, NMRA, EWTX
91,638 Shares in Edgewise Therapeutics, Inc. $EWTX Acquired by Hsbc Holdings PLC
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026
Edgewise Therapeutics: The Servier Deal Creates A Self-Funded Cardiovascular Platform
Edgewise Therapeutics Reports Second Quarter 2026 Financial Results